KRAS and non-small cell lung carcinoma: The OPG expression was significantly higher for patients with bone metastases in the subgroup of patients with EGFR+ and EGFR/KRAS wildtype NSCLC (p=0.021 and p=0.028) (Supplementary Material, Figures 1B-E).